Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Xenon Pharmaceuticals Inc. (XENE)
|
|
| Common Size Income Statement |
|
|
|
|
Annual | Quarterly | TTM |
|
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Cost of goods sold | 0.0% | 0.0% | 0.0% | 0.0% | 100.0% | 58.0% | 0.0% | 0.0% |
| Gross profit | 100.0% | 100.0% | 100.0% | 100.0% | 0.0% | 42.0% | 100.0% | 100.0% |
| Selling, general and administrative | 1468.9% | 528.4% | 197.3% | | | | | |
| Research and development | | | | 568.8% | 2215.0% | 3455.8% | 1099.7% | 97.3% |
| General and administrative | | | | 158.2% | 787.8% | 988.2% | 376.7% | 62.8% |
| EBITDA | -1269.3% | -422.4% | -81.6% | -620.7% | -3510.2% | -4314.3% | -1328.5% | -53.4% |
| Depreciation | 17.2% | 4.9% | 2.0% | 6.3% | 54.9% | 87.7% | 47.9% | 6.7% |
| EBIT | -1286.5% | -427.3% | -83.6% | -627.0% | -3565.1% | -4402.0% | -1376.4% | -60.1% |
| Pre-tax income | -1327.7% | -427.9% | -90.4% | -609.4% | -3235.3% | -4149.2% | -1275.5% | -101.1% |
| Income taxes | 1.3% | 0.0% | -0.8% | -0.3% | -2.2% | 0.0% | 0.0% | 0.0% |
| Net income | -1328.9% | -427.8% | -89.7% | -586.1% | -2963.1% | -4149.2% | -1275.5% | -101.1% |
|